Protocol Specific Research Support

CCSG为方案特定研究支持（PSRS）提供的资金用于开发NYUCI 启动的早期阶段协议。NYUCI高度重视这些研究，因为它们 这是NCI癌症中心计划最有希望的好处之一。应计至已启动的 在过去的资助期间，NYUCI的研究增加了一倍，这一类别现在占两个 三分之一的利润。2005年的38项研究中有23项是I期、I/II期和试点方案 从而可能有资格获得PSRS支持。这些资金的分配采用了严格的标准，包括 PRMC指定的科学优先级，适当疾病管理小组的建议 和/或CCSG科学计划，对此类资源的需求，以及研究将导致 随后经同行审查的供资或纳入合作小组或联合体的研究。的 拨款的最终决定由临床癌症调查委员会作出。

CCSG funds for Protocol Specific Research Support (PSRS) are used for development of NYUCI investigator-initiated early phase protocols. The NYUCI places a high priority on such studies since they represent one of the most promising benefits of the NCI Cancer Centers Program. Accrual to investigatorinitiated studies at NYUCI has doubled over the last funding period and this category now accounts for two thirds of all accruals. Twenty three of the 38 studies in 2005 were phase I, phase l/ll, and pilot protocols thereby potentially qualifying for PSRS support. Strict criteria are used to allocate these funds including scientific priority assigned by the PRMC, recommendation by the appropriate Disease Management Group and/or CCSG scientific program, need for such resources, and likelihood that the study will lead to subsequent peer-reviewed funding or incorporation into cooperative group or consortium studies. The ultimate decision for allocating PSRS funds is made by the Clinical Cancer Investigation Committee.